Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Healios Again Delays Definitive MultiStem Deal with Nobelpharma
Tokyo-based biotech Healios said on September 30 that it is again pushing back the scheduled date of a definitive collaboration agreement for the development and marketing of its off-the-shelf cell therapy MultiStem to be concluded with Nobelpharma in Japan. In…
To read the full story
Related Article
- Healios, Nobelpharma Reach No Deal on Cell Therapy MultiStem
January 16, 2025
- Healios, FDA Agree on Pivotal PIII Design for Cell Therapy MultiStem
September 10, 2024
- Healios Pushes Back Definitive MultiStem Deal with Nobelpharma
July 1, 2024
- Healios Snaps Up Assets after Athersys’ Bankruptcy Filing
April 5, 2024
- Healios, Nobelpharma Ink Basic Deal for Cell Therapy Alliance in ARDS
December 28, 2023
- Healios Grabs Worldwide Rights to Athersys’ Cell Therapy in ARDS
October 12, 2023
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- FRONTEO Taps Bayer Ex-Chair Eiki as Advisor
July 22, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
- Carna Bio’s AML Drug Candidate Earns US Orphan Tag
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…